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PARTl 
l.PREFACE 
My name is Zacharias Tsachakis and for my Bachelor Thesis I had practice at the 
University Hospital Motol. 
I was assigned to the Pediatrie Departments and specifically to children with Cystic 
Fibrosis. 
I selected a patient and through her and with the assistance ofmy supervisor Paed.Dr. 
Libuse Smolikova I understood many things about this disease and its development as 
well. 
Furthermore, I learned the therapy and physical exercises performed to these patients 
and also other patients with pulmonary problems. 
I realized how important is for the physiotherapist to have good communication and 
cooperation with the patient and also with its the family for the best results. 
After the end of my 2-week practice I had new knowledge and experience which I 
gathered to compose my Bachelor Thesis. 
PART 2: GENERAL PART 
2. 1 .CF Introduction 
Just 1 O years ago, cystic fibrosis (CF) a life-threatening disorder that causes severe 
lung damage and nutritional deficiencies was a genetic mystery, and most people with 
the disease didn't live beyond their teens. Since then researchers have made real 
progress in unraveling the genetic basis of CF, which has led to earlier detection. 
Because of this and improved and more consistent treatments for the disease, many 
people with CF now live into their 30s and have fuller and more comfortable lives. 
CF is an inherited (genetic) condition affecting the glands that produce mucus, tears, 
sweat, saliva and digestive juices. Normally, these secretions are thin and slippery, but 
in CF, a defective gene causes the secretions to become thick and sticky. Instead of 
acting as a lubricant, the secretions may plug up tubes, ducts and passageways, 
especially in the pancreas and lungs. Respiratory failure is the most dangerous 
consequence of CF. 
Each year approximately 3,200 white babies are bom in the United States with CF. 
The disease is much less common among black and Asian-American children. Two-
thirds of the infants bom with CF will be diagnosed in the frrst year of life. In all, 
about 30,000 American adults and children are living with this disorder. Although 
there's stili no cure, the emerging field of gene therapy may someday help correct 
lung problems in people with CF. 
2 .1 .2 : ETIOLOGY- A FAMILYS RISK FOR CF 
The main cause ofCF is a defect in the CF gene which codes for the "cystic fibrosis 
Trans-membrane regulatory protein" (CFTR). There may also be other genes 
involved and yet unknown environmental factors. This protein is an ionic channel, 
which regulates the transport of chloride ions across the epithelial cell membrane. 
Mutation in this protein leads to a defect in chloride and hence, waters transport, with 
secondary desiccation of surface secretions. 
Of all ethnic groups, Caucasians have the highest inherited risk for CF, and Asian 
Americans have the lowest. In the U.S. today, about one of every 3,000 Caucasian 
children is bom with CF. This compares with one of every 17,000 African Americans 
and only one of every 90,000 Asian Americans. Although the chances of inherited 
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risk may vary; CF has been described in every geographic area of the world among 
every ethnic population. 
It takes two copies of a CF gene, one inherited from each parent, for a child to show 
symptoms ofCF. Persons bom with only one CF gene (inherited from only one 
parent) and one normal gene are CF carriers. CF carriers do not show CF symptoms 
themselves, but can pas s the problem CF gene to their children. lf two CF carriers 
have a child, there is a one in four chance that the child will ha ve CF. The CF gene is 
found on chromosome number 7 (humans ha ve 23 pairs of chromosomes made of the 
inherited genetic chemical called "DNA"). Right now, scientists have identified at 
least 600 different mutations in the CF gene that are capable of causing symptoms of 
CF. Some mutations cause milder symptoms than others do. The most common 
mutation, called the Delta F508, causes about 90% of cases of CF and can be detected 
by genetic testing. This testing can be done in children, both before and after birth, 
and in adults who are thinking about starting or enlarging their family.(13, 14) 
2.2 PATHOGENESIS 
While CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) has never 
been viewed directly, its predicted amino acid sequence suggests that it consists of 
two homologous structural units, each including a transmembrane domain and a 
nucleotide-binding domain, connected by a central regulatory domain rich in 
phosphorylation sites. The tertiary structure suggests, and experimental data confrrm, 
a transmembrane transport function with likely regulatory roles for adenosine 
triphosphate (ATP) binding and phosphorylation. 
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The 800 or so genetic mutations associated with cystic fibrosis have been divided into 
five broad classes based on their influence on CFfR manufacture and function. Class 
I mutations, which affect fewer than 7% of cystic fibrosis patients, are stop mutations 
that directly interfere with CFfR protein production, either by introducing a 
premature signal for termination of RNA translation orby altering mRNA but leaving 
the reading frame intact. Class II mutations disrupt the trafficking mechanism that 
takes CFfR from its point of origin on the endoplasmic reticulum to its site of 
operation on the apical membrane. Approximately 85% of cystic fibrosis patients 
have at least one copy of the primary class II mutation, delta-F508 (deletion of 3 bp 
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Class ITI mutations, which affect fewer than 3% ofpatients, cause defective ATP- or 
phosphorylation-dependent regulation of CFfR. The protein has reached the apical 
membrane, but it does not become activated and inactivated in the normal fashion. 
Class IV mutations disrupt conductance through CFfR ion channels, despite norma! 
placement and regulation of the molecule. Finally, class V mutations result in reduced 
synthesis of functional CFfR. Prevalence of class IV and V mutations is difficult to 
assess because the effects tend to be mild and not associated with early lung or 
gastrointestinal problems. Patients may not even be diagnosed with cystic fibrosis 
unless they happen to seek care for a related condition, such as male sterility. (The vas 
deferens is extremely sensitive to changes in CFfR function. Even a slight decline in 
conductance is thought to impede ion transport and reduce fluid content, leading to 
excessive viscosity, epithelial obstruction, and progressive obliteration of the vas. 
Consequently, nearly 100% of male cystic fibrosis patients are sterile. Until recently, 
few patients lived long enough for fatherhood to be an option, so the mere fact that we 
are facing this issue indicates how much progress has been achieved. lf a couple is 
unwilling to adopt, sperm can be removed via microsurgical epididymal aspiration for 
in vitro fertilization, and the fertilized egg tested for cystic fibrosis prior to 
implantation.) 
Implications for New Drug Design 
5 
The ability to zero in on the molecular and cellular consequences of cystic fibrosis 
mutations has prompted a massive effort to design drugs that specifically address each 
problem. For class I mutations, it was quickly leamed that a number of common 
antibiotics, including gentamicin, can reverse the process in a test tube. Whether they 
will work equally well in patients with cystic fibrosis is now being tested in clinical 
trials. 
Class II intracellular trafficking problems are also remarkably easy to correct in vitro. 
Just dropping the temperature ofthe affected cells by three or four degrees Celsius 
will override the delta-F508 defect. Unfortunately, the challenge is much greater in 
humans: All prototype agents developed to date have proveď to be too toxic or 
required excessive concentrations to achieve a therapeutic effect. Nevertheless, there 
is growing confidence that a safe and effective agent will be found. While an anticlass 
II drug would not benefit every patient with cystic fibrosis, it could significantly 
reduce morbidity and mortality in the large majority ofpatients who have at least one 
copy of delta-F508. 
Ion Channel Modifiers. When CFTR reaches the cell membrane, it acts as a chloride 
channel, allowing passive transport of ions in and out of the cell along 
electrochemical gradients. Disruption of this activity plays a major--if poorly 
understood--role in the chronic dehydration of airway secretions characteristic of the 
disease. Consequently, an aggressive search is underway for compounds that can 
promote altemate chloride channels, either in the absence of or with minimal CFTR 
stimulation. ATP analogs such as uridine triphosphate (UTP) have been shown to 
induce chloride secretion from the airway cells of both healthy persons and patients 
with cystic fibrosis through such altemate channels. While UTP metabolizes too 
rapidly to be clinically useful, some of its analogs ha ve been processed into aerosols 
that are currently in clinical trials. Additional drug classes that stimulate CFTR 
chloride transport include certain aminoglycosides (for class I defects) and butyrates, 
which upregulate the so-called molecular chaperones (for class II defects). Drugs 
active in increasing non-CFTR chloride channel activity are under development as 
well. 
CFTR also regulates the function of other ion channels--particularly the sodium 
channel, which is overactive in patients with cystic fibrosis. Whether the underlying 
problem is excessive airway surface salt concentration or increased dehydration 
remains unclear. Reduction of airway surface water thickens respiratory mucus, while 
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the increased salt inactivates salt-sensitive antibiotic defensin peptides that normally 
protect the airway against infection. Drugs that block the sodium channel would be 
expected to have a beneficial effect, and indeed an aerosolized versi on of the sodium 
channel blocker amiloride has shown limited benefit. A combination of amiloride plus 
the UTP analog INS365 is currently being tested, to see whether the two agents work 
synergistically to redress the salt-water imbalance. Research is also in progress with 
hypertonie saline, which temporarily brings additional water into the airway, 
provoking cough and improving mucus clearance. 
CFTR Regulation and Conductance Modifiers. Getting CFTR to the cell membrane is 
one thing; having the protein follow physiologic commands and carry out its assigned 
tasks is another. CFTR is regulated or "gated" by protein kinase A-mediated 
phosphorylation at its regulatory domain and by ATP binding and hydrolysis at its 
two nucleotide binding domains. Candidate drugs with activity in these areas include 
genistein (for regulatory class III defects) and phosphodiesterase inhibitors such as 
milrinone (for class IV conductance defects). 
Infection and Inflammation 
Impressive as these developments have been, there remains a serious lack of 
understanding concerning the relationship between CFTR dysfunction at the cellular 
level and the persistent infection and inflammation that characterize cystic fibrosis. 
Infection ofthe airways with a restricted spectrum ofbacterial pathogens--
Pseudomonas aeruginosa strains in particular--is patho-gnomonic of the disease. But 
most ofthe bronchiectasis and progressive deterioration ofpulmonary function seen 
in these patients i s not caused by infection but by the massive influx of neutrophils 
associated with dysregulation of local host inflammatory pathways. Excessive 
production ofthe chemokine interleukin (IL)-8 and deficient production ofthe anti-
inflammatory cytokine IL-10 and the pleiotropic cytokine gamma-interferon have 
been reported as potential endogenous mediators of this response in CF airway and 
immune cells activated by infectious or physical stimuli. 
The concentration of neutrophils in airway surface fluid, even in patients with mild 
cystic fibrosis, is hundreds of times that of healthy persons. During exacerbations, 
additional migration of neutrophils from the pulmonary vasculature occurs--probably 
triggered by IL-8 in response to the adherence and exoproducts of P. aeruginosa. 
Once neutrophil migration into the airway is initiated, the process is self-perpetuating, 
with neutrophil degranulation products--including elastase and free radicals--
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attracting other neutrophils both directly and indirectly (through increased IL-8 
production by respiratory epithelial cells and by the neutrophils themselves). Despite 
their numbers, the short-lived neutrophils are unable to ingest the vol ume of bacteria 
presented to them. As they begin to die, they release not only toxic proteolytic 
enzymes and oxidants but also DNA and actin, which clog the airways and contribute 
to the thickness and tenacity ofthe sticky mucus. Coughing increases, the patient 
becomes feverish, and appetite and exercise tolerance drop. Simple activities like 
sitting in a classroom or visiting friends become overwhelmingly difficult. 
Why do the airways of cystic fibrosis patients hind bacteria so vigorously? As 
mentioned, high airway salt content may inactivate the defensin shield that protects 
healthy persons from infection. But current estimates of airway salt content in cystic 
fibrosis vary widely--not all studies have shown the abnormality--and many 
investigators feel that loss of defensins alone cannot account for the bacterial 
colonization seen in this disease. An altemative to the high-salt hypothesis (which 
does not rule out a secondary role for loss of defensins) stems from the observation 
that P. aeruginosa strains preferentially hind to glycolipid receptors lining the airways 
of cystic fibrosis patients. The abnormal binding is confmed to the airway lumen; P. 
aeruginosa rarely invades the lung parenchyma or disseminates systemically. Do the 
airways of cystic fibrosis patients have an overabundance of cell-surface receptors for 
these bacterial strains? Or, as o ne group of investigators has speculated, does the 
CFTR molecule itself normally function as a selective bacterial receptor, diverting 
bacteria into pulmonary epithelial cells that are then sloughed off--creating an innate 
form ofhost defense? And does the malfunctioning ofCFTR somehow encourage P. 
aeruginosa to multiply in the extracellular mucus, triggering the damaging cycle of 
neutrophil entry and decay? That certainly is the end result. But how that result is 
achieved remains frustratingly unclear. (5, 17, 20) 
2. 2 .2:CF signs and symptoms 
The specific signs and symptoms ofCF can vary, depending on the severity ofthe 
disease. For example, one child with CF may have respiratory problems but not 
digestive problems, while another child may have both. In addition, the signs and 
symptoms of CF may vary with age. In some newboms the first sign may be a 
blockage ofthe intestines (meconium ileus). This occurs when meconium tarry, 
greenish-black stools normally passed by an infant in the first day or two after birth 
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becomes so thick it can't move through the intestines. Other signs in newboms may 
include a failure to grow, bulky and greasy stools (steatorrhea) and frequent 
respiratory infections.The signs and symptoms of CF in children and young adults 
may include: 
Salty taste to the skin. People with CF tend to have two to five times the normal 
amount ofsalt (sodium chloride) in their sweat. This may be one ofthe first signs 
parents notice because they taste the salt when they kiss their child. 
Blockage in the bowel. 
Foul smelling, greasy stools. 
Delayed growth. 
Thick sputum. lnfants and young children tend to swallow their sputum, and parents 
may not be aware of it. 
Chronic coughing or wheezing. 
Frequent chest and sinus infections with recurring pneumonia or bronchitis. 
Growths (polyps) in the nasal passages. 
Enlargement or rounding ( clubbing) of the fingertips and toes. Although clubbing 
eventually occurs in most people with CF, it also occurs in some people bom with 
heart disease and other types of lung problems. 
Cirrhosis of the liver due to in:flammation or obstruction of the bile ducts. 
Displacement of one part of the intestine in to another part of the intestine 
(intussusception) in children older than age 4. 
Protrusion ofpart ofthe rectum through the anus (rectal prolapse). This is often 
caused by stools that are difficult to pass or by frequent coughing. 
CF affects a number of organs. 
Lungs 
It is common for people with CF to encounter some difficulties with their lungs. To 
find out how lungs work, click here. A combination of physiotherapy and medication 
can help controllung infections and prevent lung damage. See the 
treatment/medication section ofthis site for further information. To avoid the risk of 
cross infection, people with CF need to ensure they do not come into close contact 
with others with CF. 
The Digestive System 
CF affects the pancreas, which makes it difficult for people with CF to digest food. 
This can cause malnutrition, which can lead to poor growth, physical weakness and 
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delayed puberty. There is medication that can compensate for the failure ofthe 
pancreas.See the treatment/medication section ofthis site for further information. 
In older patients, insulin production can become deficient due to increasing pancreatic 
disease. Some develop diabetes mellitus and their blood sugar levels are no longer 
controlled. However, this rarely happens to children with CF. 
Common symptoms of diabetes include thirst, hunger, weight loss and excessive need 
to urinate, but some people do not show obvious symptoms of diabetes. For more 
information about diabetes mellitus, click here 
Other Affected Organs 
In every ten babies bom with CF, one is ill in the frrst few days oflife with a bowel 
obstruction called meconium ileus. In these cases, the meconium (a thick black 
material present in the bowels of all newbom babies) is so thick that it blocks the 
bowel instead of passing through. Babi es with meconium ilius often need an urgent 
operation to relieve and bypass the blockage. 
People with CF are prone to osteoporosis (thin, brittle bones) dueto the nutritional 
and other problems involved with the disease. Adults with CF are at an increased risk 
of osteoporosis because ofthe adverse effects of steroids taken to controllung 
disease. 
Although Cystic Fibrosis does not cause sexual impotency it can lead to fertility 
problems. In most men with CF, the tubes that carry sperm are blocked, which causes 
infertility. Because underweight women are more likely to have irregular menstrual 
cycles, the nutritional problems associated with CF may affect fertility. However, 
women with CF do produce healthy, fertile eggs so effective contraception is 
necessary. 
CF can cause the blockage of small ducts in the liver. This only happens to 
approximately 8% ofpeople who have CF. However, this is a serious health risk and 
may necessitate a liver transplant. (5, 13) 
2 .2. 3.: THE GENETICS OF CF 
To understand why one person gets CF and another doesn't you must go back to your 
high school biology class and basic Mendelian Genetics. Gregor Mended was a monk 
who lived in the mid to late 1800s and established the foundation of genetics as we 
know it today. But the "modem age" ofmanagement really began in 1989, with the 
cloning of the gene encoding the cystic fibrosis transmembrane conductance regulator 
10 
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Cystic fibrosis is caused by a defect in a single gene, which regulates the passage of 
chloride and sodium in and out of cell membranes. lt occurs in about 113,300 white 
births, 1115,300 black births, and 1/32,000 asian-american births. But why do some 
children get CF while their brothers or sisters don't? To answer that question you must 
understand the interaction of dominant and recessive genes, the basis of Mendel' s 
genetic theory. 
Human beings ha ve two matching sets of 23 chromosomes within the nucleus of our 
cells. Bach chromosome has thousands of genes. Genes regulate every thing about our 
bodies; how we look, how our bodies function, and what traits we pass on to our 
children. Having two sets of matching chromosomes lets some genes express their 
instructions (dominant) while suppressing the instructions of the matching gene 
(recessive). Leťs take eye color for example. Brown eyes are a dominant trait while 
blue is recessive. li a person has the dominant gene for brown eyes, even if they also 
have the recessive gene for blue, they'll stili have brown eyes. The only way they can 
have blue eyes is to have both genes for blue eyes. The CF gene works in the same 
way. The CF gene is a recessive trait. The parents of a CF child each carry one CF 
gene and one norma! gene. When they have children they pass on one gene each, iťs 
the combination of these genes that determine if the child will have CF or not. The 
possibility of having a child with CF is 1 in 4 or 25%. The possibility of having a 
child without the CF gene is the same 25% and the possibility of having a child as a 
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"carrier" of the CF gene without the disease is 50%. A carrier of the CF gene doesn't 
have the disease but can pass the gene on to their own children. 
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NORHAL CARRIER CAFIRIEF: CF 
Cystic Fibrosis is an inherited genetic disorder. 1 in 25 people in the UK carry the CF 
gene, usually without knowing it. lf a baby is born with CF, it rneans that both parents 
carry the faulty CF gene. Even if they do, there is no guarantee that the child will be 
born with CF. lf both parents are carriers, the child has: 
A one in four chance of being born with CF. 
A two in four chance of being a carrier, but not having the disease. 
A one in four chance of neither having CF nor being a carrier of the faulty gene. (15, 
16) 
2.3.DIAGNOSIS - TESTS 
2.3.1 New born testing 
About a third of babies in the UK are tested for CF at birth using a heel prick blood 
test. The govemrnent recently announced its intention to have all babies tested at 
birth, enabling treatrnent to begin irnrnediately. 
2.3.2 Antenatal testing 
This deterrnines early on in pregnancy whether a baby will have CF. Antenatal testing 
is only offered in cases where there is a high chance of CF. 
2.3.3 Genetic testing 
A sarnple of cells is obtained by gently rubbing the inside of the cheek with a brush. 
This specirnen can be used to find the CF gene. lt can also deterrnine which farnily 
rnernbers rnay be CF carriers. 
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2.3.4 Carrier testing 
A simple mouthwash test can tell if you are a carrier. This is advisable if a relative has 
CF or is a carrier. It is particularly important ifyour partner is a known carrier and 
you are considering having children. 
2.3.5 Chest X-ray 
The chest X-ray allows your doctor to look inside the lungs. It gives more information 
about how the disease may be affecting the lungs and helps to guide treatment 
decisions. 
2.3.6 Pulmonary function tests (breathing tests) 
The doctor may want to do one or more ofthese to measure how well the lungs are 
working. They pro vide information about any blockage of the bronchial tubes, and 
show how fast air can get in and out of the lungs. They also help the doctor evaluate 
changes in the lungs over a period time. Pulmonary function tests are especially useful 
in making decisions about treatment, and measuring the success of treatment. 
However, it is difficult to do these breathing tests on infants and young children. 
2.3.7 Sputum cultures (phlegm cultures) 
These cultures check the sputum for evidence of an active infection in the lung sample 
of mucus is placed in a dish that germs like staph and pseudomonas grow and 
multiply. Some time later, the dish is checked for these and other germs that can cause 
lung infections. 
2.3.8 Blood tests 
These are done periodically to identify other possible CF-related problems early on, 
so they can be treated before they become big health problems small sample ofblood 
is usually taken with a syringe and then sent to a laboratory for testing. 
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2.3.9 Sweat Test 
The sweat test is an accurate, safe, and painless way to diagnose CF. In the sweat test, 
a small electric current is used to carry the chemical pilocarpine into the skin of the 
forearm. This stimulates sweat glands in the area to produce sweat. Over a period of 
30 to 60 minutes, sweat is collected on filter paper (or gauze) and tested for chloride. 
A chloride reading ofmore than 60 mEq/L point to CF. Children with CF have more 
salt in their sweat than normal. If the baby i s diagnosed with CF, the other children in 
your family should have a sweat/genetic test. 
2.4. CLINICAL FEATURES 
There is a broad spectrum of presenting signs and symptoms and cystic fibrosis and 
this may be a reflection of many gene variants. Over 400 mutations have been 
identified. Many patients are diagnosed early in life with signs and symptoms related 
either to the respiratory or gastrointestinal systems. 
In the neonate, meconium ileus is the most common presenting feature occurring in 
about 10-15% of cases. Signs of intestinal obstruction may occur within 48 hours of 
birth. The infant fails to pass meconium after birth because the bowel is obstructed by 
sticky inspissated intestinal contents, but in milder cases there may only be delay in 
the passing of meconium. 
Another common presenting sign in infants and young children is a voracious appetite 
and failure to thrive dueto malabsorption from the alimentary tract.Gastro-
oesophageal reflux is a problem in some patients. 
Abnormalities in ion transport in the pancreas lead to inflammation and later to 
fibrosis ofthe acinar portion ofthe gland and to hyposecretion ofthe major digestive 
enzymes secreted by the pancreas. The presenting symptom is steatorrhoea; 
abdominal discomfort and distension often accompany the passing of 
characteristically fatty. In some patients steatorrhoea is not a presenting features or 
maybemild. 
The complication of diabetes mellitus in the older patient may possibly result from 
progressive fibrosis of the pancreas and is thought to be associated with a decline in 
the patienťs clinical condiiton. Another feature occurring in adults is liver damage, 
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which starts as focal biliary cirrhosis and may in a few patients progress to portal 
hypertension and occasionally hepatic failure. 
Meconium ileus equivalent is a form of small intestinal obstruction occurring in some 
adults with cystic fibrosis. lt causes abdominal distension and discomfort, vomiting 
and constipation, and should not be confused with appendicitis. 
Most women with cystic fibrosis have norma! or near norma! fertility, but puberty 
may be delayed. Most mal es are subfertile because of development defects of the vast 
deferent, epididymis and seminal vesicles. Possible methods of reproduction may be 
discussed with the specialist. 
Approximately one-third of adult patients with cystic fibrosis develops rheumatic 
symptoms. The two most common forms are an episodic and recurrent arthritis and 
hypertrophic pulmonary osteoarthropathy. They are characterized by joint pain, 
tendemess, swelling and Iimitation of movement, usually symmetrical and affecting 
particularly the knees, ankles and wrists. 
The respiratory signs and symptoms vary. Some patients may be asymptomatic for 
many years, other may have a dry cough and later a persistent cough with purulent 
sputum. The respiratory pathogens most commonly isolated in 1990 were 
Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenza and 
Pseudomonas cepacia. Staphylococcus aureus used to be the most frequently isolated 
organism, but it is now only in-patients of les s than 1 year of age in which this is the 
case. Colonization with Burkholderia cepacia and Pseudomonas aeruginosa. Mucus 
hypersecretion, impaired mucociliary clearance and inflammation create an 
environment in which bacteria will thriven patients with cystic fibrosis there is in 
addition a market attraction between Pseudomonas aeruginosa and the airways. 
Haemoptysis is common and usually mild, although episodes of frank haemoptysis 
may occur wheeze is sometimes present, and patients may be breathless on exertion. 
With increasing breathlessness appetite becomes poor and the patient loses weight. 
Chest pain may be associated with an exacerbation of a bronchopulmonary infection, 
a pneumothorax or musculoskeletal dysfunction. Most patients develop finger 
clubbing and with more severe disease may become cyanosed. 
The chest radiograph is usually norma! at birth but an early change is bronchial wall 
thickening, particularly in the upper zones. As the disease progresses, overinflation of 
the lungs may occur with ill-defined nodular shadows, numerous ring and parallelline 
shadows indicating bronchial wall thickening and bronchiectasis. Crackles and 
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wheezes may be heard on auscultation. Some patients develop nasal polyps; these 
may grow rabidly and are frequently recurrent. They may be related to chronic sinus 
infection. 
Pulmonary function tests initially show signs of obstruction, but with advanced 
disease a restrictive pattem may be superimposed on the obstructive defect and a 
diffusion abnormality will also become apparent. Pulmonary function measurements 
have been shown to be predictors ofmortality's the disease progresses 
ventilation/perfusion imbalance occurs leading to hypoxaemia, pulmonary 
hypertension and cardiac failure. 
Asthma is a common in-patient with cystic fibrosis as it is among the normal 
population. Many cystic fibrosis patients have a positive skin test to Aspergillus 
fumigatus. This is often seen in the sputum, but allergic bronchopulmonary 
aspergillosis is les s common occurring in approximately ll% of patients. Recurrent 
wheezing, deteriorating chest symptoms and fleeting fluffy shadows on the chest 
radiograph recognizes ABP A. 
Investigations for cystic fibrosis are similar to those for bronchiectasis, but may also 
include pancreatic function studí es, tests for fecal fat, examination of the liver, spleen 
and gall bladder, and screening for diabetes mellitus.(l, 2, 3, 4, 7, 15, 20, 21, 22) 
2.5. MANAGEMENT 
1) Physical therapy for the clearance ofthe bronchial airways from the sticky mucus. 
2) Administration of drugs for the prevention of infections and alterations in lung soft 
tissues. 
3) Specific diets and additional supplies of pancreatic enzym es to maintain proper 
nutritional abilities. 
It is the knowledge ofthe condition and understanding ofthe treatment for cystic 
fibrosis, which influence patient compliance and treatment outcomes. The presenting 
problems of each patient will vary, and will fluctuate from a chronic stable state to an 
acute changing state. An exacerbation of a bronchopulmonary infection will produce 
changes, which can be detected by accurate assessment of the signs and symptoms. 
Physiotherapy may help in the treatment of patienť s problems of excess bronchial 
secretions, reduced exercise tolerance, breathlessness and chest wall stiffness and pain 
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ofmusculoskeletal origin. Arthropathy, unstable diabetes and the abdominal pain of 
meconium ileus equivalent are examples of medical problems, which will affect the 
physiotherapist's treatment pian. 
Throughout the world initially treatment was applied using standard techniques. But 
as knowledge has developed a wide spectrum of physiotherapy techniques influencing 
ventilation arose. 
Such techniques are: 
Gravity assisted positioning 
Gravity assisted positioning is the use of different body positions to achieve: 
Drainage of secretions from a particular area of lung, using gravity 
Increased air flow to different parts of the lung 
Chest physiotherapy techniques should be carried out in different positions, so that 
each lung segment is kept as clear of secretions - and as fully inflated - as possible. 
(13, 14, 18) 
2.6. DRUG ADMINISTRATION. 
Medication 
Cystic Fibrosis affects the lungs and the digestive tract - these areas are likely to 
require medication. 
lnfections can be cleared or controlled by a variety of drugs. Here is a guide to the 
most commonly used medication for people with CF. 
Lungs 
Medication can be administered in various ways: inhaled into the lungs using 
nebulisers; taken orally or taken intravenously. 
These drugs treat the lungs in the following ways: 
Bronchodilator drugs open the airways by relaxing the surrounding muscle. They 
relieve tightness and shortness ofbreath. They widen the breathing tubes to take 
mucus removal and breathing easier. These are most often prescribed prior to chest 
physical therapy. 
Mucolytics: thin the mucus, making it easier to drain. 
Decongestants: reduce the swelling of the membranes that line breathing tubes. 
Antibiotics: help control infection. These are most often taken after chest physical 
therapy. 
Antibiotics help to treat or control persistent infection. 
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Antibiotics 
Antibiotics is drugs that destroy infecting-causing bacteria. Respiratory infections can 
occur frequently in CF, and antibiotics are important part ofthe therapy. The type of 
antibiotic, hoe often is taken, and over how long time period it is taken varies for each 
person. Some people with CF need continuous antibiotics while others need only to 
control flare-ups of infection. Y our doctor will adjust antibiotic treatment to your 
chilďs individua! needs. 
Oral antibiotics 
Are often in tablets or capsules that are swallowed. Oral antibiotics are often used to 
treat mild flare-ups of lung infection. These are effective against staph and some more 
other infections, but are not always effective against pseudomonas. Although oral 
antibiotics have not worked well against pseudomonas, new antibiotics are being 
developed that work well. Y our CF doctor will tell you if oral antibiotics are needed 
and which are best suited to your chilďs needs. 
Jntravenous antibiotics: 
Are liquid solutions that are put directly into blood? More serious lung infections may 
require IV antibiotics, which work quite well against pseudomonas and staph. A stay 
in the hospital is often part ofthis treatment, but many CFF-accredited care centers 
recommend home IV antibiotics for some of their patients when appropriate. 
Aerosolized antibiotics: 
Are liquids turned into a mist and inhaled. Aerosolized antibiotics are generally those 
that do not work well when swallowed. An aerosol mist delivers the antibiotic directly 
into the airways. These antibiotics are stili being studied to test the effectiveness of 
this type of treatment. 
Steroids reduce inflammation in the airways. 
Dnase breaks down mucus and makes it easier to clear 
Digestive System 
Cystic Fibrosis affects the pancreas, so enzyme pills should be taken with meals and 
snacks to replace pancreatic enzymes and enable people with CF to gain more energy 
from the food they eat. The dietician or doctor can ad vise on the appropriate 
type/dosage of enzyme supplement. 
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Nutritional supplements such as high-energy drinks can also help to compensate for 
ineffective digestion. 
Anyone suffering from diabetes mellitus will need to balance food intake with 
appropriate diabetic treatment such as tablets or insulin. 
Other Organs 
Bones can be effected by a lack of minerals, which can cause osteoporosis 
(weaklbrittle bones). Bisphosphonates, which are used to treat osteoporosis in post-
menopausal women, have been shown to be beneficial for the treatment of 
osteoporosis in CF too. Research is being carried out to investigate the benefits of 
high do ses of vitamin D and calcium. 
lf someone with CF is having liver problems, they will be treated in the same way as 
other people with this condition. Promising results have been reported following early 
treatment with ursodeoxycholic acid.(8, 12, 19) 
2.7. AIRWAY SUCTION 
Airway suction is usually necessary to clear secretions from the intubated patient with 
an endotracheal tube. 
Infants are at particular risk of infection, so great care must be taken with hand 
washing and wearing gloves, etc. 
The vacuum pressure should not be excessive but will need to be strong enough to 
draw secretions up very narrow bore catheters. Recommended values are 10-20 pa. 
Most commonly used catheters are 6 and 8 French gauge. Size 5 FG and below are 
usually ineffective in removing thick secretions. Size 1 O FG and above should be 
reserved for use with older children. When suctioning artificial airways the extemal 
diameter ofthe catheter should not exceed 50% ofthe intemal diameter ofthe airway. 
Diluents and mucolytics, e.g. saline in aliquots of 0.5 ml to 5 ml may be used to 
enhance secretion clearance. The efficacy ofthese is not conclusively proven and they 
should never be used routinely. Larger quantities of irritants are sometimes used as 
part of bronchoalveolar lavage procedures but this should only be undertaken by 
experienced personnel and with great caution. 
Particular care should be taken with nasopharyngeal suction of neonates as reflex 
bradycardia and apnoea can occur. 
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Nasopharyngeal suction should be avoided ifthe child has stridor or has recently been 
extubated as is may precipitate laryngospasm. 
Physical activity is an important part of the treatment process. 
Exercise is particularly important for people with CF as it prevents deterioration of 
the lungs and improves physical bulk and strength. Children with CF should be 
encouraged to take part in as much physical activity as possible - ideally types of 
exercise that make you out ofbreath (i.e. running, swimming, football or tennis). It is 
important to inform teachers at school that exercise should be encouraged, as they 
may be unsure whether exercise is good for people with CF or not. 
Posture and chest mobility 
The spine, ribcage and shoulders should remain fully flexible as far as possible and 
good posture should be maintained. 
Older children or adults may need to do stretching exercises to maintain full 
movement of the joints and musel es around the shoulders and chest. 
Y ounger children can do the same by taking part in gam es or activities that involve 
moving and stretching the trunk and arms. Activities like wheelbarrow racing make 
good stretching exercises, as well as helping to drain secretions.(l5) 
2.8 DIET 
Diet should be as normal as possible, provided rich in proteins should and calories 
should. CF patients should have pancreatic enzymes supplement and fat soluble 
vitamins (A, D, E, and K).(13) 
2.9 TRANSPLANTATION 
The success rate of Lung transplantation for CF patients is encouraging: 70% survive 
one or two years after transplantation and the longest surviving patients had their 
transplant operation 12 years ago. Like any other major surgery it carries considerable 
risks and is appropriate only for a patient who is severely ill and has tried all other 
forms of conventional treatment. To these patients, lung transplantation offers a better 
quality of life. 
There i s a shortage of donor organs available for those awaiting transplants. lf more 
people carry donor cards, then more lives that can be saved in this way. 
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Transplantation doesn't remove all concem- the risk of rejection or infection stili 
remains. Anyone considering transplantation should consult doctors or counsellors at 
a local CF clinic. For more information about transplantation, you can download the 
CF Trusťs booklet here. 
2.10.PREVENTION 
If you ha ve a family history of CF, you may want to consider genetic counseling 
before starting a family. In many cases carriers ofthis disorder can be identified 
through testing. 
At this time, preventing CF is not possible. In babies with two abnormal CF genes, the 
disease is already present at birth in some organs, such as the pancreas and liver, but 
develops only after birth in the lungs. Someday, gene therapy may be used to prevent 
the lung disease from developing. Y et, CF might be prevented in the future. Since CF 
occurs only when both parents pass on a CF gene to a child, it could be prevented by 
identifying all carriers of CF genes. Genetic counselors might then persuade couples 
who are carriers not to have children. However, as noted, current tests can detect only 
some of the more than 400 gene mutations and so the tests are only 80-85 percent 
accurate. 
Y et, progress in gene therapy and the realization that not all CF mutations are life-
threatening should reassure couples. Potential parents who carry the defective gene 




Family history: mother, bom 59- healthy, her mother- sarkoidosis 
Father, bom 66 - polinosis, hypertension 
Brother, bom 87- alergy,has different father, sister, bom 98- exzema 
Persona! history: She is bom from the third physiological pragnancy, 
polyhydramnion, spontaneus delivery in the correct term, 3500grams I 51 cm length, 
she was not resuscitated, icterus O, after the birth she had ileus - she had to undergo 
resection of 17 cm of jejunum because of atresia. She was not gaining the weight, she 
was coughing and there were found chlorides in the sweat 11.114 mmolll. These 
symptoms led to diagnosis of cystical fibrosis I heterozygocy delta F508 and del21 kb 
CFTR. 
At the age of 2 months she was taken to hospital I 1. children clinicsl to start with 
therapy. At the age ofthree months she was in hospital I 1. chldren clinics I because of 
obstructive dyspnoe I = breathlessness I . During the first two years she was getting 
Endobulin because of secondary hypogamaglobulinemia lgG I = low level of 
antibodies class lgG I, now the level of antibodies is normal.412003 lgG 7,26, lgA 0,4, 
lgM 1,3, lgE 18 , I only a little bit decreased lgA, the other classes of antibodies are 
normal./ She had repeatedly troubles with breathing, expiratory breathlessness -
treated with Pulmicort. 712000 she was in ho spi tal due to metabolical disballance and 
breathlessness, in the cultivation of mucus was found Burkholderia cepacia, control 
cultivation was allready negative- so it was evaluated as a contammination.812000 
she was in a hospital for ileus and had the operation to disturbe adhesions, without 
any resection. 712002 was treated for the pro lapsus of rectum, was made reposition. 
She has been watched in the cardiac centre of Moto! due to a not dangerous 
rhabdomyoma ofthe heart and in neurology because ofpossibility oftuberal sclerosis, 
but it seems not to be present. 
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Pseudomonas in the mucus ofthe airways was found for the first time in 13.9.2001, 
she was treated in 1 0/2002 and there i s not anz presence of Pseudomonas in mucus at 
the moment 
Hip joints are OK, she was breast-feeded for 6 months, then was adding normal 
food, but stili continued breast feeding for another two years .. 
Vaccination according to vac. callendary, without any reactions. 
Children diseases : O 
Operations: 
112000- KDCh Moto I- resection of jejunum because of atresy 
8/2000 - KDCh Motol -- ileus, operation to disturb adhessions, without resection 
lnjuries: O 
Watching: in cardail center ofMotol for presence ofrhabdomyoma in myocardium of 
heart and in neurology for possibility of tuberal sclerosis. 
Alergies: O 
Permanent therapy: Colimycin inhalations 3x 1 MIU, Kreon 10000 16x per day, 
Ranisan 2xl/4 tbl., Lactobacilus 1x1, vitaminE 2x a week, vitamin A 4x a week, 
Vigantol 2 drops a day, Amilorid inhalations 2x a day, flutter 3x a day 
State: she has a good appetite, eats 5 times a day, defecation 1-3 per day, not 
smelling, belly-aching only rady, when coughing, she expectorates usually only white 
mucus, nowdays mucus is of a green colour the green colour, she is able to exercise 
without breathlessness I she participates dancing course. Presence of Pseudomonas 
aeruginosa in the mucus in 5.1.2004. Her weight and height are normal. 
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Present status : 
In the last controll was found in her mucus Pseudomonas aeruginosa 1 Ol 6, 
Stafylococcus aureus, Haemofillus influenzea 1016 , she had twice viral infection , 
first in 1112003- this time she was treated with Mucosolvan, second in 1212003 I 
treated with antibiotic sirupi. 
In the mucus from 5.1. 2004 was found again Pseudomonas aeruginosa, so she is 
coming to hospital to be treated with the combinated antibiotic therapy during her staz 
in hospital. 
Status: 
Without increased temperature, eutrofic I ofthe normal weight and proportions I, 
normal hydratation, skin clean, muscle tonus normal. Head is mesocefalic, not 
painfull for percussion, endings of nervus trigeminus are not painful, inervation from 
n. facialis is good, pupillas are izocoric, with fotoreaction, conjuntivas are pink, nose 
and ears are without secretion, tongue with a mild layer, throat is calm, tonsillas are 
hypertrofie I enlarged I, not painfull, without any pus on them, lymphatic nodes in 
neck are on both sides enlarged, breathing is vesicular and clear, she is coughing and 
expectorates viscous mucus ofthe green color, heart beat is regullar, without anz 
sounds, bellz is soft, under the level of thorax, not painfull, liver is not enlarged, scar 
after operation is calm, extremities are without swelling, female genital without 
secretion. Signs of meningeal iritation are negative. 
Vysetfeni: FW:12152(15.1.)CRP: 1,8 ... 8 KO: 
26.01.2004-16:02 
WBC 10.4; RBC 4.74; HGB 12.8; HCT 0.387; MCV 81.6; MCH 27.0; MCHC 33.1; 
RDW 12.6; PLT 311; MPV 7.1; 
PCT 0.220; PDW 16.8; Lymfo 0.408; Mono 0.054; Neutro 0.502; Eo 0.022; Bazo 
0.014; 
LY# 4.243; MO# 0.562; GR# 5.595; 
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15.01.2004-15:36 
WBC 14.8; RBC 4.76; HGB 12.9; HCT 0.390; MCV 81.8; MCH 27.1; MCHC 33.1; 
RDW 13.1; PLT 471; MPV 7.8; 
PCT 0.365; PDW 16.5;Lymfo 0.254; Mono 0.061; Neutro 0.679; Eo 0.001; Bazo 
0.005; 
LY# 3.759; MO# 0.903;'GR# 10.138; 
Biochemie: 
26.1. 
Na+ 138 MMOL/L [*],K+ 4.2 MMOL/L [*],Cl- 107 MMOL/L [*], CA-CELK 2.35 
MMOL/L [*], OSM 290 
MMOL/KG [*],ALP 3.31 UKAT/L [*], AST 0.46 UKAT/L [*],ALT 0.43 UKAT/L 
[*], CK 1.48 UKAT/L [*] 
GMT 0.13 UKAT/L [*], BILI-CELK 4.9 UMOL/L [*], UREA 5.0 MMOL/L [*], 
KREA 54 UMOL/L [*], 
CB 69.6 G/L [*] 
21.1. 
Na+ 139 MM O LIL [*], K+ 4.3 MM O LIL [*], Cl- 107 MM O LIL [*], CA-CELK 2.29 
MMOL/L [*], AST 0.56 
UKAT/L [*],ALT 0.39 UKAT/L [*], LD 5.9 UKAT/L [*], BILI-CELK 5.9 UMOL/L 
[*] 
15.1. 
Na+ 138 MM O LIL [*], K+ 4.1 MM O LIL [*], Cl- 105 MM O LIL fl'], CA-CELK 2.45 
MMOL/L [*], P 1.88 MMOL/L 
[*],OSM 292 MMOL/KG [*],ALP 2.64 UKAT/L [*], AST 0.56 UKAT/L [*],ALT 
0.50 UKAT/L [*] LD 8.2 
UKAT/L [*], CK 1.12 UKAT/L [*], GMT 0.11 UKAT/L [*], AMS 0.86 UKAT/L [*], 
BILI-CELK 5.7 UMOL/L [*], 
UREA 4.8 MMOL/L [*], KREA 54 UMOL/L [*], TRIGL 1.42 MMOL/L [*], CHOL 
4.9 MMOL/L O* CB 63.7 G/L 
[*], ALB 42.9 G/L [*], IGF1 94 (-1,00SD) UG/L 
VIT A 1.5 UMOL/L [*], VIT E 10.50 UMOL/L [*] 
Moc a sediment: Moc chemicky: SPEC.HMOTN 1.010 kg/1, pH 6.5, 
LEUKOCYTY NEC , NITRITY NEC , BILKOVINA NEC , GLUKOSA NORM, 
KETOLATKY NEC, UROBILINOG NORM, BILIRUBIN NEC, KREV (ERY) 
NEC, 
Mocovy sediment: ERYTROCYTY nenalezeny pocet/z.p. , LEUKOCYTY 0-4 
pocet/z.p. , V ALCE nenalezeny pocet/z.p. , EPIT DLAZD nenalezeny pocet/z.p. , 
RUZNEhlen 
Mikrobiologie: nos - bezna flora, PCR: B.cepacia obe kola NEG 
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sputum 16.1.2004 
Str.viridans,Neisseria kvant. 10 exp.6, leuko,epi,g+koky,g-tycky3. 
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ORL : enlargement of palate tonsillas, without any focus of infection, ears, nose, 
lymfatic nodes norma!. 
Surgary: state after the pro lapse of rectum, there are two little skin proces ses in 
perianal area,sfincterhas a little bit increased pressure. She can be ordered for 
operation in dr. Fric to take out processes. It will take max. 3 days to stay in hospital. 
Antropology: 105,2 cm (55,8P), 16,9 kg(49.7P), circumference ofarm 16,5 
cm(32.99P), good state ofnutrition, sticks 111,05 
Immunology: lgG 7,13, lgA 0,44- a little bit decreased, lgM 1,32, lgE 14, lgG1 
4,39, IgG2 2,13, lgG3 0,304, lgG4 1,5, C3 0,82, C4 0,11- a little bít decreased. 
It is necessary to control lgA during the next visit in hospital. 
Virology: EBV- memory antibodies, CMV, HSV, VZV are negative 
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ECG: sinusal, axis ofheart is + 60 degrees, PRO, 12, QRS 0,07, STT normal, 
fyziological superiority of the left ventricle, normal fase of repolarization. 
Course of stay in hospital: 
4 years old girl was accepted to our department for the regullar A TB therapy due to a 
chronic 
presence of Pseudomonas in airways. She is coming with the low inflamatory 
parametres and without any clinical signs of acute infection. In the mucus from 5 .1. 
2004 was found Pseudomonas.lt has been started with intravenous antibiotic therapy 
Amikacin 3 x 180 mg a day and Fortum 3 x 1200 mg a day. According to the level of 
amikin was the dose of Amikin reduced to 3 x 140 mg. , but this was not effective, 
that is why the dose was increased to 3 x 160 mg, which is optimal. At the same time 
she is getting her usual therapy ofColimycin inhalations 3 x 1 MIU, Kreon 10000 17 
x a day, Ranisan 2 x Y.., Lactobacillus 1 x 1, vitaminE 2 x a week, vitamin A 4 x a 
week, Vigantol2 drops a day, Amilorid inhalations 2 x a day, flutter 3 x a day. 
During the whole stay in hospital was without increased temperature, was eating and 
drinking enough. Breathing is always clean, without any presence of mucus, she is 
expectorating fmally only white mucus. 
It was prrescribed recipi for Kreon 10000 80 pieces, Ranisan 75 mg 5 pieces, 2x 
mouthpiece. 
Diagnosis: Cystical fibrosis with insuficciency of pancreas 
Therapy : Amikacin 3x 160 mg intravenous 
Fortum 3x 1200 mg intravenous 
Colimycn inhalations 3x 1 MIU, Kreon 10000 17x a day, Ranisan 2xl/4 
tablett, Lactobacillus 1x1, vitaminE 2x a week, vitamin A 4x a week, Vigantol2 
drops a day, Amiloroid inhalations 2x a day, flutter 3x a day. 
Recommendation.: Visit in the ambulance of cystic fibrosis in 3 months, ifthere is 
any acute problem, so immidately 
Sample of mucous every month 
Controlls of IgA 
Visit in surgary to take out perianal skin processes 
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3.2 REHABILITATION- RESPIRATORY PHYSIOTHERAPY 
The ultimate goal of the physiotherapy procedure during my practice at Motol 
hospital applied at my patient Katerina Schusterova and also for every other patient 
with respiratory problems or diseases was to help them remove the inflammatory 
sticky mucus from the bronchi, in order to assist the gas exchange which is 
interpreted, to help with the removal of particles and germs which are trapped in the 
alveoli and can cause various kinds of infections, to reduce the possibility of flare-up 
of an infection , to protect as much as possible the lungs structure and to minimize as 
much as possible the patients stay in the hospital. 
We can obtain all the above mentioned goals by applying different kinds of 
physiotherapeutic techniques. The administration of the drugs was done usually 
before the beginning of the physiotherapeutic exercises in a form of a mist. The time 
limit of the physiotherapeutic process was not more than 45 min. and always 
according to the daily status of my patient. Considering my patienťs age the exercises 
were applied in the form of a game. It was very important for me and all the 
physiotherapists in general to be accepted by the infant in order to fulfill my task 
without problems (eg. child's cry) 
Right upper lobe -posterior segment 
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Lingula 
Right nůddle lobe 
Lower Iobes -apical segments 
Lower lobes -posterior basal segments 
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Left lower lobe -lateraJ basaJ segment 
Right lower lobe -lateral basal segment 
Lower lobes -anterior basal segments 
3.3 Position for draining ditferent lung segments 
....1 Upper lobes -apicaJ segments 
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Upper lobes -anterior segments 
Left upper lobe -posterior segment 
3.4 The Active Cycle of Breathing Techniques (ACBT) 
The ACBT is used to mobilize and clear excess bronchial secretions. lt has been 
shown to be effective in the clearance of bronchial secretions and to improve lung 
function. lt neither causes nor increases hypoxaemia, nor increases airflow 
obstruction. 
In the management of children with cystic fibrosis in the Ukraine, the physiotherapy 
techniques used had been very uncomfortable. The introduction of the ACBT during a 
6-month period led to subjective improvements and significant improvements in 
oxygen saturation. 
The ACBT is a flexible method of treatment, which can be adapted for use in any 
patient, young, or old, medical or surgical, where there is a problem of excess 
bronchial secretions. lt can be used with or without an assistant. 
lt is a cycle of breathing control, thoracic expansi on exercises and the forced 
expiration technique (FET). The original studies on FET used this cycle of techniques, 
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but people began to use a regimen of huffing alone or other variations on the FET and 
the literature became confusing. In order to emphasize the use of thoracic expansion 
exercises and the periods ofbreathing control, in addition to the FET, the whole 
regimen was renamed the active cycle of breathing techniques. The regimen did not 
change in practice and the earl y stu di es on the FET were randomized controlled trials 
ofthe ACBT. 
Th ·e •activ ·e cycle" of breathing exerclses. 
3.5 BREATHING CONTROL 
All breathing techniques should be taught by a physiotherapist. 
Aims 
to encourage relaxation and ease breathlessness 
Al',' l:ftothft( tedtrt*JuEI 
sht"AJtl be tllloaftt by 11 
p~erapist. 
to reduce over inflation of the upper chest and encourage a more norma! breathing 
pattem 
to allow "relaxation" of the airways so that secretions can be cleared more easily 
Method 
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Rest your hand lightly on your tummy 
Try to relax the muscles around the neck and upper chest 
Breathe quietly and gently (as you breathe in, your tummy should swell slightly and, 
as you breathe out, sink down again). You should feel more movement around the 
waist and less around the upper chest 
· ng control in sitting 
position 
3.6 THORACIC EXPANSION (DEEP BREATHING) EXERCISES 
Aims 
to loosen secretions 
to keep the chest mobile 
Method 
Relax the upper chest 
Apply pressure with your hand to the lower part of the ribcage 
Breathe in slowly and deeply, filling up the lungs with air and expanding the lower 
chest as much as possible 
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Release pressure with your hand and breathe out quietly 
expansion in sitting 
position 
3. 7 Forced expiration technique (huffing & breathing control) 
Aims 
to move secretions from the smaller to the larger airways so that they can be cleared 
from the lungs more efficiently 
Method 
Stage 1: Huffing 
Tak:e a medium sized breath in 
Squeeze the air out, contracting your tummy muscles and keeping your mouth and 
throat open. The huff should not be violent 
The breath out should be prolonged but not continued until the lungs are completely 
empty. This may mak:e you cough as secretions are moved. lf secretions do not come 
up in one or two coughs, try to stop coughing or you will become tired 
Stage 2 
Do some breathing control 
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Stage 3 
Stages 1 and 2 may be repeated until secretions can be felt high in the chest 
Stage 4 
When you feel secretions high in the chest, you should take in a deep breath and huff 
or cough to clear them 
in sitting position 
3.8 CHEST SHAKING 
Some people find that this technique is especially helpful in moving secretions if used 
with breathing exercises, although the technique is effective when used on its own. 
Method 
Place your hands on the chest 
On the 'ouť phase of a deep breath, shake the chest firmly, squeezing out the air in 
short bursts and applying the pressure inwards 
Y o u may not be successful with this method at first but keep trying - it takes practice 
to do shaking comfortably and effectively. 
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Chest shaking on "out" phase of deep breath 
3.9 TODDLERS AND YOUNG CHILDREN 
Toddlers and young children aren't the easiest age group to deal with at the best of 
times- and this applies equally to treatment! However, although iťs often difficult 
and frustrating to persuade a child to lie stili and cooperate with treatment, iť s well 
worth persevering. Co-operation with treatment in future years is very often 
dependent on how things are handled at toddler stage. 
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lťs essential that a child leams from an early age that physiotherapy is something that 
has to be done every day. With patience and imagination, you can mak:e 
physiotherapy a time that children enjoy and regard as a special time of day - a time 
when they have 
the undivided attention of mum or dad. This can be considered a transitional stage, 
when children's treatment is changed and modified as they get older and can leam 
new techniques. 
Practising breathing techniques 
through play 
When children are too big to be treated comfortably on the knee, they can have their 
treatment lying over a foam wedge. 1 After children are two years old, treatment 
should 
progress from 'passive' to a more 'active' form. In the next couple of years, children 
can leam new breathing techniques which should be introduced gradually into their 
physiotherapy programme. A variety of 'blowing games' can be started. For example: 
- tak:ing big deep breaths in and blowing little 
pieces of tissue paper 
- blowing bubbles 
- breathing out and steaming up a mirror 
Children can play these games whilst on the wedge during physiotherapy sessions, 
either during or 
between short periods of chest clapping. 
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Steaming up a mirror 
the power of the breath 
3.10 Autogenic Drainage (AD) 
Autogenic drainage (AD) airns to rnaximize airflow within the airways to irnprove the 
clearance of rnucus and ventilation. Chevalier developed this concept in Belgiurn in 
late 1960s, but little was published until1979. Autogenic drainage is breathing at 
different lung volurnes and an active expiration is used to rnobilize the rnucus. 
Chevalier described three phrases: 'unstick' , 'collecť and 'evacuate'. Breathing at 
low lung volurnes is said to rnobilize peripheral rnucus. This is the first or 'unstick' 
phase. lt is followed by a period of tidal breathing which is said to 'collecť rnucus in 
the middle airways. Then, by breathing at higher lung volurnes, the 'evacuate' phase, 
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expectoration of secretions from the central airways is promoted. A huff from the lung 
volume is now encouraged to clear the secretions from the trachea. Coughing is 
discouraged. 
AD has been altered in Germany and is not split into the three phases as the patients 
were found to be uncomfortable breathing at low lung volumes. This technique is 
known as modified Autogenic drainage. The patient breathes around tidal volume 
while breath holding for 2-3 seconds at the end of each inspiration. Coughing is used 
to cleat the mucus from the larynx. 
The flow-volume curve is frequently used to support an increase in airflow with the 
unforced expiratory maneuver of autogenic drainage. However. It must be 
remembered that it i s only possible to go outside the flow-volume curve if pressure-
dependent collapse exists. 
Autogenic drainage is usually practiced in the sitting position. It takes 10-20 hours to 
teach the main principles and sessions of 30-45 minutes twice a day are necessary. 
Children under the age of about 8 years would find it difficult to concentrate for any 
length oftime on the different levels ofbreathing involved. 
In the long-term study of patients with cystic fibrosis AD was compared with 
'conventional' percussion and postural drainage. AD was found to be at least as 
effective as the conventional treatment and patients had marked preference for AD. 
3.11 Positive Expiratory Pressure (PEP): 
Positive expiratory pressure is usually given through a mask to provide resistance to 
breathing out. This helps to keep small airways open and to loosen secretions. One of 
the benefits ofPEP is that iťs performed in the sitting position. This makes it 
convenient to use when 
space is limited, as it may be at work, in school or when travelling. Treatment consists 
ofbreathing through a face mask with different sizes ofresistors, for about ten 
breaths. The mask is then removed before the forced expiration technique (huff and 
breathing control) is performed to 
clear secretions. Iťs important that a physiotherapist carries out a full assessment, so 
that the correct level of resistance can be chosen. This will be re-assessed regularly, 
particularly during a chest infection. 
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Using the positive expiratory pressure (PEP) 
mas k 
3.12 High Pressure PEP 
High-pressure PEP is a modified form of PEP mask treatments describe for the 
treatment of patients with cystic fibrosis by Oberwaldner et al. By using high 
pressures of PEP secretions may be mobilized more easily in-patient holds the mask 
firmly against the face. Six to ten rhythmical breaths at tidal volume are followed by 
an inspiration to totallung capacity and then a forced expiratory maneuver against the 
resistance to low lung volume, which usually results in the expectoration of sputum. 
An individuals optimum expiratory resistance is carefully determined by spirometry. 
lt is the resistance that allows the patient to expire to a volume greater than his usual 
forced vítal capacity. The technique is only recommended for use where fulllung 
function equipment is available for regular reassessment of the expiratory resistance 
for each individua!. Meticulous care must be taken as an incorrect resistance can lead 
to deterioration in lung function. 
3.13 Oscillating PEP-Flutter Therapy: 
The Flutter is a small, simple portable device u sed to assist the clearance of bronchial 
secretions. lt is pipe-shaped with a single opening at the mouthpiece and a series of 
small outlet holes at the top of the bowl. The bowl contains a high-density stainless 
steel ball bearing enclosed in a small cone. During expiration the movement of the 
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ball along the surface ofthe cone creates a positive expiratory pressure and an 
oscillatory vibration of the air within the airways. The device is held horizontally and 
tilted slightly downwards until a maximal oscillatory effect can be felt. The Flutter 
combines the techniques of oral high-frequency oscillation and PEP. It can be used in 
the sitting position or in the position of supine lying. 
The Flutter is placed in the mouth and inspiration is either through 
The nose or through the mouth by breathing around the Flutter. A slow deep breath in 
with a breath hold of 3-5 seconds is followed by a breath out, through the Flutter, at a 
faster rate than norma!. After four to eight of these breathes many patients' use 
huffing either through the Flutter or without the Flutter. This may precipitate 
expectoration and should be followed by a pause for breathing control. 
Originally the recommended technique for the Flutter was a gentle exhalation through 
the device. Treatment was continued for a period of 1 O minutes. Secretions were 
expectorated by spontaneous coughing. It was this regimen that was shown by Pryor 
et al to be less effective than the ACBT. The inclusion ofhuffing, as described in the 
regimen above, is likely to increase the effectiveness of airway clearance. 
Konstan et al compared three regimens: the Flutter, voluntary coughing and a regimen 
of postural drainage, which included up to 1 O positions. Each session lasted 15 
minutes. The Flutter regimen was the most effective as measured by the weight of 
sputum expectorated, but PEP had been shown to be more effective than a similar 
postural drainage regimen. In a subsequent study the ACBT was shown to be more 
effective than PEP. 
When Autogenic drainage was compared with the Flutter it was concluded that both 
regimens were equally effective, but the Flutter was easier to teach. A clinical trial 
was undertaken using the Flutter in-patients following thoracotomy, but no advantage 
could be found in its inclusion. 
The use of the Flutter in airway clearance may improve compliance in some patients, 
especially children. Care must be taken to wash and dry the parts ofthe device after 
use to minimize the risk of infection. 
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3.14 Postural Drainage and Percussion: 
lt was the most common technique until the 80's. Consists of plac ing the patient in 
various positions, which allows gravity to assist in the expectoration of the mucus by 
the patient. Percussion is used to assists postural drainage. Nowadays is used mainly 
in the U.S.A. and U.K. this technique in another countries is believed that causes 
various side effects to patients with pulmonary diseases because of the weakness of 
the lung tissues that this people have in the development of the disease. 
3.15 Inhalation Therapy 
Is now considered an important component of the treatment in CF with the 
physiotherapist administrating drugs via airways before starting the physiotherapy. 
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Bronchodilator drugs may be prescribed and these should be inhaled before treatment 
to clear secretions. In some patients the airflow obstructions is partially reversible 
with bronchodilators. Another possible effect of b-adrenergic drugs in an increase in 
cilia action and this may improve mucociliary clearance. 
Normal saline or hypertonie saline may be inhaled before physiotherapy to assist in 
clearance of secretions. Ifhypertonic saline is used a test dose should be given with 
recording of PEF or FEV 1 before and 5 minutes after inhalation to identify any 
increase in airflow obstructions. 
The optimal time for administration of Pulmozyme in relation to physiotherapy has 
nor yet been adequately studied and needs to be assessed for each individua!. Some 
patients benefit most by inhaling it about 30 minutes before the physiotherapy for 
airway clearance. Others find it takes several hours to reach a maximal effect a take it 
after one physiotherapy session with the result that the next session is more 
productive. 
Pulmozyme should be aerosolized on its own, as it requires isotonic conditions and 
neutral pH for maximal activity. On theoretic grounds, sufficient time should be 
allowed to elapse between the inhalation of Pulmozyme and other drugs, e.g. 
antibiotics, which may be either acidic or alkaline, to ensure maximum benefit from 
the drugs. 
Mucolytic agents, for example acetylcystein, reduce mucus viscosity. They should be 
used with caution as bronchospasm may be induced. 
Aerosol antibiotics should be inhaled after secretions have been cleared. Spirometry is 
necessary before and after the initial dose to detect any increase in airflow 
obstruction. Ifthis should occur the effect is usually minimized by the inhalation of 
bronchodilator before treatment. 
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aling 'nebuliseď 
bronchodilator drug through mouthpiece 
3.16 Mobilization of Thorax: 
lts usefulness is very essential because due to the frequent use of breathing musel es 
shortening and tensions rises. Also inactivity of other muscles occurs. Lastly the 
mobilization of ribs is important fork assistance of ventilation. Also a proper posture 
is developed. 
PART 4: LONG AND SHORT TERM PHYSIOTHERAPY 
4.1 SHORT TERM PHYSIOTHERAPY 
Children with CF, may need to spend a lot of time in hospital in order to have some 
diagnostics tests. Of course everything depend on the condition of the child. The 
diagnos ti es tests in cl ude measurement of breath, it means the lung' s function, and 
nutritional assessment. When is everything fine and when the doctor realize that there 
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is no reason to stay in the hospital because the lungs are clear, then the child may 
leave. Before this, the doctor has to be sure also that the child has started a diet with 
digestive enzymes and vitamins that will help him to gain weight normally. 
Afterwards, he will probably see his doctor for follow-up visits at least once every 
three months. The basic daily care program of a child with CF varies from child to 
child, but usually includes pulmonary therapy (treatments to improve lung function) 
and nutritional therapy (modified diet with vitamin and mineral supplements). 
Children with CF can also take do ses of pancreatic enzymes by mouth to help them 
digest foods better. They may occasionally need oral or inhaled antibiotics to treat 
lung infections, and mucolytic medication (a mucus-thinning drug) to keep mucus 
fluid and flowing. 
Generally the short term physiotherapy is linked to the long term physiotherapy by the 
ability of the physiotherapist to teach the exercises to a person or persons who are 
clo se to the patient so they can help him, the ability of those persons to learn the 
procedures and fmally the ability of the patient to apply all the physical therapy on 
himself. 
4.2 LONG TERM PHYSIOTHERAPY 
The long-term physiotherapy is mainly done by certain persons or person related to 
the patient or by the patient itself on the contrary with the short term physiotherapy 
the doctor and the physiotherapist are needed more scarcely. 
Pulmonary rehabilitation combines exercise training and behavioral and educational 
programs designed to help patients with CF to improve day-to-day activities. 1t is a 
team approach: patients work dosely with their doctors, nurses, respiratory, physical, 
and occupational therapists, psychologists, exercise specialists, and dietitians. 
Exercise has been shown to increase fitness, decrease shortness of breath, improve 
heat tolerance, help mucus clearance, and perhaps improve lung function (some 
studies say yes, some studies say no, but no study shows any harmful effects on lung 
function) in people with CF. In those who do not have CF, regular exercise decreases 
depression improves self-image and worth, it makes sense that these benefits would 
also apply to people with CF. 
Studies have shown that people with CF who are more fit: can do more exercise, have 
a better quality of life, tolerate heat stress better, and may even li ve longer. 
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The best kind of exercise is any form that someone will stick to over a lifetime. 
Experts suspect that aerobic exercise is best. ("Aerobic" means "with oxygen," and 
aerobic exercise does not require more oxygen than the lungs and heart can provide to 
the body' s muscles.) Some examples of aerobic exercise include jogging, swimming, 
biking, stair stepping, walking, aerobics, and aerobic dancing. 
The ideal exercise program calls for three to five 30-minute sessions each week 
(fewer sessions will not increase fitness; more increase the risk of overuse injury.) Do 
not plan to start with 30-minute sessions; instead, start at 1 O minutes and gradually 
increase to 30 minutes. Exercise hard enough to feel pleasantly tired. (lfyou feel only 
tired, that is too hard; ifyou feel only pleasant, it is not hard enough.) 
One very important study showed that the most fit people with CF were the most 
likely to survive the next eight years, while the least fit were the least likely to 
survive. Until we know this for sure, though, it is worth remembering an old saying: 
"whether or not exercise puts more years in my life, it definitely put more life in my 
years!" 
PART 5: PROGNOSIS 
Generally iťs impossible to make a proper prognosis at a patient with CF. In this 
disease the organism is very sensitive to various conditions ( e.g. dust, air pollution) 
and diseases ( e.g. common cold, rhinitis, flu) comparing to other people which all the 
above factors cause continued destruction of the lungs tissues. The average lifetime 
of these people is about 40 years old worldwide. The life of the patient with C.F 
depends on many factors such as: (a. surrounding environment, b. medical 
management, c. Physiotherapeutic management, d. family assistance and e. 
individual's psychology. 
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PART 6: CONCLUSION 
The problem lies on the fact that this disease is chronic and so other people from the 
close environment of the patient should be involved and also to make the patient 
available to help himself. 
The therapist must realize how important and responsible work physiotherapy is, and 
the patient is necessary to consider the therapist as a friend and to understand that the 
improvement of the quality of life is something very important. At the end of the day 
what is more important is the quality and not the quantity of life. 
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